Fate Free Cash Flow Yield vs Price To Sales Ratio Analysis

FATE Stock

USD 3.17 0.49 18.28%

Fate Therapeutics financial indicator trend analysis is much more than just examining Fate Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fate Therapeutics is a good investment. Please check the relationship between Fate Therapeutics Free Cash Flow Yield and its Price To Sales Ratio accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

Free Cash Flow Yield vs Price To Sales Ratio

Free Cash Flow Yield vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fate Therapeutics Free Cash Flow Yield account and Price To Sales Ratio. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Fate Therapeutics' Free Cash Flow Yield and Price To Sales Ratio is 0.84. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Fate Therapeutics, assuming nothing else is changed. The correlation between historical values of Fate Therapeutics' Free Cash Flow Yield and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Fate Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Free Cash Flow Yield i.e., Fate Therapeutics' Free Cash Flow Yield and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Fate Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Fate Therapeutics sales, a figure that is much harder to manipulate than other Fate Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Fate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Issuance Of Capital Stock is projected to grow to (26.5 K).

	2021	2022	2023	2024 (projected)
Interest Expense	4.5M	5.8M	6.7M	7.1M
Depreciation And Amortization	5.9M	13.8M	18.3M	19.2M

Interest Expense Depreciation And Amortization

Fate Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.9	0.93	0.93	0.99	0.72	0.61	0.77	0.24	-0.77	0.93	0.48	0.93	0.86	0.59	0.46	0.99	0.81	0.92	0.86	0.7	0.85	0.93	0.56	-0.45	0.99
Short Long Term Debt Total	0.9		0.85	0.85	0.88	0.55	0.86	0.63	0.51	-0.93	0.8	0.25	0.95	0.75	0.5	0.47	0.88	0.89	0.87	0.81	0.81	0.96	0.87	0.83	-0.44	0.89
Other Current Liab	0.93	0.85		0.98	0.89	0.7	0.54	0.87	0.19	-0.71	0.91	0.5	0.82	0.82	0.75	0.41	0.94	0.75	0.87	0.84	0.71	0.78	0.94	0.5	-0.39	0.95
Total Current Liabilities	0.93	0.85	0.98		0.9	0.64	0.51	0.93	0.23	-0.72	0.9	0.45	0.83	0.89	0.67	0.4	0.92	0.74	0.85	0.81	0.77	0.79	0.93	0.46	-0.41	0.94
Total Stockholder Equity	0.99	0.88	0.89	0.9		0.68	0.61	0.74	0.19	-0.77	0.91	0.52	0.93	0.85	0.51	0.5	0.98	0.84	0.93	0.79	0.69	0.86	0.87	0.55	-0.54	0.98
Other Liab	0.72	0.55	0.7	0.64	0.68		0.24	0.5	-0.18	-0.26	0.62	0.67	0.56	0.47	0.84	0.28	0.78	0.44	0.55	0.77	0.08	0.4	0.75	0.23	-0.26	0.75
Property Plant And Equipment Net	0.61	0.86	0.54	0.51	0.61	0.24		0.21	0.63	-0.94	0.53	0.0	0.79	0.39	0.2	0.31	0.58	0.83	0.68	0.57	0.72	0.9	0.57	0.99	-0.33	0.59
Current Deferred Revenue	0.77	0.63	0.87	0.93	0.74	0.5	0.21		0.13	-0.48	0.77	0.39	0.63	0.9	0.59	0.31	0.76	0.48	0.66	0.65	0.69	0.55	0.8	0.14	-0.31	0.79
Net Debt	0.24	0.51	0.19	0.23	0.19	-0.18	0.63	0.13		-0.57	0.2	-0.7	0.5	0.35	-0.1	-0.05	0.13	0.23	0.17	0.39	0.58	0.49	0.34	0.6	0.22	0.16
Retained Earnings	-0.77	-0.93	-0.71	-0.72	-0.77	-0.26	-0.94	-0.48	-0.57		-0.71	-0.13	-0.88	-0.63	-0.24	-0.42	-0.73	-0.92	-0.84	-0.62	-0.89	-0.98	-0.69	-0.91	0.45	-0.75
Accounts Payable	0.93	0.8	0.91	0.9	0.91	0.62	0.53	0.77	0.2	-0.71		0.44	0.86	0.84	0.52	0.4	0.92	0.75	0.88	0.82	0.7	0.78	0.9	0.48	-0.26	0.92
Cash	0.48	0.25	0.5	0.45	0.52	0.67	0.0	0.39	-0.7	-0.13	0.44		0.23	0.23	0.54	0.44	0.58	0.47	0.53	0.25	0.02	0.25	0.35	0.0	-0.61	0.56
Non Current Assets Total	0.93	0.95	0.82	0.83	0.93	0.56	0.79	0.63	0.5	-0.88	0.86	0.23		0.83	0.39	0.38	0.9	0.84	0.85	0.82	0.78	0.94	0.87	0.73	-0.37	0.91
Non Currrent Assets Other	0.86	0.75	0.82	0.89	0.85	0.47	0.39	0.9	0.35	-0.63	0.84	0.23	0.83		0.38	0.29	0.82	0.58	0.71	0.72	0.76	0.71	0.83	0.3	-0.27	0.84
Other Assets	0.59	0.5	0.75	0.67	0.51	0.84	0.2	0.59	-0.1	-0.24	0.52	0.54	0.39	0.38		0.23	0.65	0.36	0.47	0.7	0.16	0.32	0.72	0.22	-0.2	0.64
Long Term Debt	0.46	0.47	0.41	0.4	0.5	0.28	0.31	0.31	-0.05	-0.42	0.4	0.44	0.38	0.29	0.23		0.48	0.56	0.62	0.27	0.34	0.45	0.34	0.3	-0.59	0.48
Cash And Short Term Investments	0.99	0.88	0.94	0.92	0.98	0.78	0.58	0.76	0.13	-0.73	0.92	0.58	0.9	0.82	0.65	0.48		0.82	0.92	0.84	0.64	0.83	0.92	0.54	-0.5	1.0
Common Stock Total Equity	0.81	0.89	0.75	0.74	0.84	0.44	0.83	0.48	0.23	-0.92	0.75	0.47	0.84	0.58	0.36	0.56	0.82		0.92	0.56	0.75	0.95	0.67	0.81	-0.67	0.82
Common Stock Shares Outstanding	0.92	0.87	0.87	0.85	0.93	0.55	0.68	0.66	0.17	-0.84	0.88	0.53	0.85	0.71	0.47	0.62	0.92	0.92		0.71	0.74	0.88	0.81	0.64	-0.57	0.92
Non Current Liabilities Total	0.86	0.81	0.84	0.81	0.79	0.77	0.57	0.65	0.39	-0.62	0.82	0.25	0.82	0.72	0.7	0.27	0.84	0.56	0.71		0.52	0.68	0.97	0.53	-0.01	0.84
Other Current Assets	0.7	0.81	0.71	0.77	0.69	0.08	0.72	0.69	0.58	-0.89	0.7	0.02	0.78	0.76	0.16	0.34	0.64	0.75	0.74	0.52		0.87	0.66	0.66	-0.35	0.68
Other Stockholder Equity	0.85	0.96	0.78	0.79	0.86	0.4	0.9	0.55	0.49	-0.98	0.78	0.25	0.94	0.71	0.32	0.45	0.83	0.95	0.88	0.68	0.87		0.76	0.86	-0.51	0.84
Total Liab	0.93	0.87	0.94	0.93	0.87	0.75	0.57	0.8	0.34	-0.69	0.9	0.35	0.87	0.83	0.72	0.34	0.92	0.67	0.81	0.97	0.66	0.76		0.53	-0.18	0.93
Property Plant And Equipment Gross	0.56	0.83	0.5	0.46	0.55	0.23	0.99	0.14	0.6	-0.91	0.48	0.0	0.73	0.3	0.22	0.3	0.54	0.81	0.64	0.53	0.66	0.86	0.53		-0.32	0.54
Preferred Stock Total Equity	-0.45	-0.44	-0.39	-0.41	-0.54	-0.26	-0.33	-0.31	0.22	0.45	-0.26	-0.61	-0.37	-0.27	-0.2	-0.59	-0.5	-0.67	-0.57	-0.01	-0.35	-0.51	-0.18	-0.32		-0.49
Total Current Assets	0.99	0.89	0.95	0.94	0.98	0.75	0.59	0.79	0.16	-0.75	0.92	0.56	0.91	0.84	0.64	0.48	1.0	0.82	0.92	0.84	0.68	0.84	0.93	0.54	-0.49

Click cells to compare fundamentals

Fate Therapeutics Account Relationship Matchups

Fate Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	302.3M	622.5M	921.5M	705.6M	506.2M	310.1M
Short Long Term Debt Total	26.9M	97.3M	114.8M	109.3M	103.5M	108.7M
Other Current Liab	17.5M	51.4M	40.0M	52.3M	21.3M	17.2M
Total Current Liabilities	27.8M	85.6M	81.3M	114.1M	39.1M	36.6M
Total Stockholder Equity	244.8M	384.4M	678.8M	483.9M	368.4M	210.3M
Other Liab	4.5M	58.5M	52.1M	3.9M	4.4M	4.2M
Property Plant And Equipment Net	22.8M	67.1M	70.7M	66.1M	158.5M	166.4M
Current Deferred Revenue	2.8M	21.1M	21.5M	42.2M	685K	650.8K
Net Debt	(72.9M)	(70.0M)	(18.8M)	48.0M	61.7M	64.7M
Retained Earnings	(383.5M)	(556.9M)	(769.1M)	(1.1B)	(1.2B)	(1.2B)
Accounts Payable	5.8M	6.3M	8.6M	8.3M	4.7M	4.0M
Cash	99.8M	167.3M	133.6M	61.3M	41.9M	39.8M
Non Current Assets Total	75.2M	128.1M	288.0M	203.5M	174.7M	183.4M
Non Currrent Assets Other	13.0M	32.3M	116.7M	132.5M	15.2M	26.5M
Other Assets	1.6M	95.8M	25.1M	22.5M	1.0	0.95
Cash And Short Term Investments	221.4M	482.9M	615.9M	436.2M	315.2M	224.2M
Common Stock Total Equity	65K	76K	88K	96K	110.4K	115.9K
Common Stock Shares Outstanding	68.2M	82.4M	94.7M	96.8M	98.4M	54.2M
Liabilities And Stockholders Equity	302.3M	622.5M	921.5M	705.6M	506.2M	310.1M
Non Current Liabilities Total	29.7M	152.4M	161.3M	107.6M	98.7M	63.3M
Other Current Assets	4.3M	4.4M	8.8M	27.4M	14.5M	15.3M
Other Stockholder Equity	628.2M	941.2M	1.4B	1.5B	1.6B	1.7B
Total Liab	57.5M	238.0M	242.6M	221.6M	137.8M	99.9M
Property Plant And Equipment Gross	34.2M	99.4M	70.7M	66.1M	206.1M	216.4M
Total Current Assets	227.1M	494.3M	633.4M	502.1M	331.5M	234.9M
Accumulated Other Comprehensive Income	22K	70K	(762K)	(1.9M)	15K	15.8K
Short Term Debt	1.7M	6.7M	11.2M	11.3M	12.4M	6.4M
Common Stock	76K	88K	96K	97K	99K	58.1K
Property Plant Equipment	11.4M	32.3M	162.2M	176.1M	202.5M	212.6M
Net Tangible Assets	274.5M	536.9M	678.8M	483.9M	556.5M	584.4M
Retained Earnings Total Equity	(285.4M)	(383.5M)	(556.9M)	(769.1M)	(692.2M)	(657.6M)
Short Term Investments	121.6M	315.6M	482.3M	374.9M	273.3M	159.4M
Capital Surpluse	445.8M	628.2M	941.2M	1.4B	1.7B	1.7B
Deferred Long Term Liab	1.3M	13.5M	9.9M	7.2M	8.3M	5.0M
Non Current Liabilities Other	175K	549K	702K	800K	920K	721.9K
Net Invested Capital	244.8M	384.4M	678.8M	483.9M	368.4M	381.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:

How To Invest In Fate

Details

Is Fate Stock a good investment?

Details

What is Fate Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.64)

Revenue Per Share

0.123

Quarterly Revenue Growth

0.581

Return On Assets

(0.22)

Return On Equity

(0.47)

The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fate Free Cash Flow Yield vs Price To Sales Ratio Analysis

Free Cash Flow Yield vs Price To Sales Ratio

Free Cash Flow Yield vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Price To Sales Ratio

Fate Therapeutics fundamental ratios Correlations

Fate Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fate Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Liabilities	+ 0.98	Other Current Liab

Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.94	Property Plant And Equipment Net
Retained Earnings	- 0.93	Short Long Term Debt Total
Common Stock Total Equity	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.91	Retained Earnings
Other Current Assets	- 0.89	Retained Earnings